The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 6, 2015, Pages 1068-1076

  Lopetuso, L R ^a,b   Scaldaferri, F ^a,b   Bruno, G ^a,b   Petito, V ^a,b   Franceschi, F ^a,b   Gasbarrini, A ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Gelatin tannate; Gut barrier; Gut barrier enhancer; Gut microbiota; Mucosal protectors; Mucus

Indexed keywords

BISMUTH; CORTICOSTEROID; MESALAZINE; PROBIOTIC AGENT; SUCRALFATE; TANNIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; GELATIN; TANNATE GELATIN; TANNIN DERIVATIVE;

BACTERIAL GROWTH; BACTEROIDES THETAIOTAOMICRON; DRUG EFFECT; DRUG MECHANISM; ESCHERICHIA COLI; EUBACTERIUM; EUBACTERIUM RECTALE; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; GUT BARRIER LEAKAGE; HUMAN; INFECTIOUS DIARRHEA; INFLAMMATORY BOWEL DISEASE; INTESTINAL MUCUS; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; MUCOSAL BARRIER; MUCUS; NONHUMAN; PEPTIC ULCER; PERMEABILITY BARRIER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; ANIMAL; DISEASE MANAGEMENT; DRUG EFFECTS; GASTRIC MUCOSA; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; METABOLISM; MICROBIOLOGY; MICROFLORA; PERMEABILITY; PHYSIOLOGY;

ANIMALS; DISEASE MANAGEMENT; GASTRIC MUCOSA; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; GELATIN; HUMANS; MICROBIOTA; PERMEABILITY; TANNINS;

EID: 84937577361     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. SCALDAFERRI F, PIZZOFERRATO M, GERARDI V, LOPETUSO L, GASBARRINI A. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 2012; 46(Suppl): S12-17.
2. LOZUPONE CA, STOMBAUGH JI, GORDON JI, JANSSON JK, KNIGHT R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220-230.
3. PURCHIARONI F, TORTORA A, GABRIELLI M, BERTUCCI F, GIGANTE G, IANIRO G, OJETTI V, SCARPELLINI E, GASBAR-RINI A. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013; 17: 323-333.
4. PARASHAR UD, GIBSON CJ, BRESEE JS, GLASS RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12: 304-306.
5. GABRIELLI M, D'ANGELO G, DI RIENZO T, SCARPELLINI E, OJETTI V. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. Eur Rev Med Pharmacol Sci 2013; 17(Suppl 2): 30-35.
6. SCALDAFERRI F, NARDONE O, LOPETUSO LR, PETITO V, BIBBO S, LATERZA L, GERARDI V, BRUNO G, SCOLERI I, DIROMA A, SGAMBATO A, GAETANI E, CAMMAROTA G, GASBARRINI A. Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication. Eur Rev Med Pharmacol Sci 2013; 17(Suppl 2): 2-10.
7. ARUMUGAM M, RAES J, PELLETIER E, LE PASLIER D, YAMADA T, MENDE DR, FERNANDES GR, TAP J, BRULS T, BATTO JM, BERTALAN M, BORRUEL N, CASELLAS F, FERNANDEZ L, GAUTIER L, HANSEN T, HATTORI M, HAYASHI T, KLEERE-BEZEM M, KUROKAWA K, LECLERC M, LEVENEZ F, MANICHANH C, NIELSEN HB, NIELSEN T, PONS N, POULAIN J, QIN J, SICHERITZ-PONTEN T, TIMS S, TORRENTS D, UGARTE E, ZOETENDAL EG, WANG J, GUARNER F, PED-ERSEN O, DE VOS WM, BRUNAK S, DORE J, META HITC, ANTOLIN M, ARTIGUENAVE F, BLOTTIERE HM, ALMEIDA M, BRECHOT C, CARA C, CHERVAUX C, CULTRONE A, DE-LORME C, DENARIAZ G, DERVYN R, FOERSTNER KU, FRISS C, VAN DE GUCHTE M, GUEDON E, HAIMET F, HUBER W, VAN HYLCKAMA-VLIEG J, JAMET A, JUSTE C, KACI G, KNOL J, LAKHDARI O, LAYEC S, LE ROUX K, MAGUIN E, MERIEUX A, MELO MINARDI R, M'RINI C, MULLER J, OOZEER R, PARKHILL J, RENAULT P, RESCIGNO M, SANCHEZ N, SUNA-GAWA S, TORREJON A, TURNER K, VANDEMEULEBROUCK G, VARELA E, WINOGRADSKY Y, ZELLER G, WEISSENBACH J, EHRLICH SD, BORK P. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.
8. SEKIROV I, RUSSELL SL, ANTUNES LC, FINLAY BB. Gut microbiota in health and disease. Physiol Rev 2010; 90: 859-904.
9. SILVA AM, BARBOSA FH, DUARTE R, VIEIRA LQ, ARANTES RM, NICOLI JR. Effect of Bifidobacterium longum ingestion on experimental salmonellosis in mice. J Appl Microbiol 2004; 97: 29-37.
10. TRUUSALU K, MIKELSAAR RH, NAABER P, KARKI T, KULLISAAR T, ZILMER M, MIKELSAAR M. Eradication of Salmonella Typhimurium infection in a murine model of typhoid fever with the combination of probiotic Lactobacillus fermentum ME-3 and ofloxacin. BMC Microbiol 2008; 8: 132.
11. SONNENBURG ED, ZHENG H, JOGLEKAR P, HIGGINBOT-TOM SK, FIRBANK SJ, BOLAM DN, SONNENBURG JL. Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell 2010; 141: 1241-1252.
12. MARTENS EC, ROTH R, HEUSER JE, GORDON JI. Coordinate regulation of glycan degradation and polysaccharide capsule biosynthesis by a prominent human gut symbiont. J Biol Chem 2009; 284: 18445-18457.
13. BURGER-VAN PAASSEN N, VINCENT A, PUIMAN PJ, VAN DER SLUIS M, BOUMA J, BOEHM G, VAN GOUDOEVER JB, VAN SEUNINGEN I, RENES IB. The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J 2009; 420: 211-219.
14. DHARMANI P, SRIVASTAVA V, KISSOON-SINGH V, CHADEE K. Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun 2009; 1: 123-135.
15. LEBLANC J, FLISS I, MATAR C. Induction of a humoral immune response following an Escherichia coli O157:H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk. Clin Diagn Lab Immunol 2004; 11: 1171-1181.
16. FRANK DN, ST AMAND AL, FELDMAN RA, BOEDEKER EC, HARPAZ N, PACE NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007; 104: 13780-13785.
17. SWIDSINSKI A, LADHOFF A, PERNTHALER A, SWIDSINSKI S, LOENING-BAUCKE V, ORTNER M, WEBER J, HOFFMANN U, SCHREIBER S, DIETEL M, LOCHS H. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44-54.
18. SARTOR RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594.
19. JOHANSSON ME, LARSSON JM, HANSSON GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 2011; 108(Suppl 1): 4659-4665.
20. LANG T, HANSSON GC, SAMUELSSON T. Gel-forming mucins appeared early in metazoan evolution. Proc Natl Acad Sci U S A 2007; 104: 16209-16214.
21. KITAJIMA S, TAKUMA S, MORIMOTO M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp Anim 2000; 49: 9-15.
22. JOHANSSON ME, GUSTAFSSON JK, SJOBERG KE, PETERS-SON J, HOLM L, SJOVALL H, HANSSON GC. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One 2010; 5: e12238.
23. TURNER JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799-809.
24. JOHANSSON ME, PHILLIPSON M, PETERSSON J, VELCICH A, HOLM L, HANSSON GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008; 105: 15064-15069.
25. VELCICH A, YANG W, HEYER J, FRAGALE A, NICHOLAS C, VIANI S, KUCHERLAPATI R, LIPKIN M, YANG K, AUGEN-LICHT L. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002; 295: 1726-1729.
26. VAN DER SLUIS M, DE KONING BA, DE BRUIJN AC, VEL-CICH A, MEIJERINK JP, VAN GOUDOEVER JB, BULLER HA, DEKKER J, VAN SEUNINGEN I, RENES IB, EINERHAND AW. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006; 131: 117-129.
27. GROSCHWITZ KR, HOGAN SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009; 124: 3-20; quiz 21-22.
28. RODA G, SARTINI A, ZAMBON E, CALAFIORE A, MAROC-CHI M, CAPONI A, BELLUZZI A, RODA E. Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol 2010; 16: 4264-4271.
29. GUTTMAN JA, SAMJI FN, LI Y, VOGL AW, FINLAY BB. Evidence that tight junctions are disrupted due to intimate bacterial contact and not inflammation during attaching and effacing pathogen infection in vivo. Infect Immun 2006; 74: 6075-6084.
30. HERMISTON ML, GORDON JI. In vivo analysis of cadherin function in the mouse intestinal epithelium: essential roles in adhesion, maintenance of differentiation, and regulation of programmed cell death. J Cell Biol 1995; 129: 489-506.
31. SHAO L, SERRANO D, MAYER L. The role of epithelial cells in immune regulation in the gut. Semin Immunol 2001; 13: 163-176.
32. BRUEWER M, LUEGERING A, KUCHARZIK T, PARKOS CA, MADARA JL, HOPKINS AM, NUSRAT A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003; 171: 6164-6172.
33. DUNLOP SP, HEBDEN J, CAMPBELL E, NAESDAL J, OLBE L, PERKINS AC, SPILLER RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-1294.
34. WEBER CR, TURNER JR. Inflammatory bowel disease: is it really just another break in the wall? Gut 2007; 56: 6-8.
35. FASANO A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol 2012; 42: 71-78.
36. WILD GE, WASCHKE KA, BITTON A, THOMSON AB. The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNF-alpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther 2003; 18: 309-317.
37. MIKI K, MOORE DJ, BUTLER RN, SOUTHCOTT E, COUPER RT, DAVIDSON GP. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediatr 1998; 133: 750-754.
38. BARNES PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998; 94: 557-572.
39. GOKE MN, SCHNEIDER M, BEIL W, MANNS MP. Differential glucocorticoid effects on repair mechanisms and NF-kappaB activity in the intestinal epithelium. Regul Pept 2002; 105: 203-214.
40. BAUMGART DC, VIERZIGER K, STURM A, WIEDENMANN B, DIGNASS AU. Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. Scand J Gastroenterol 2005; 40: 958-964.
41. DI PAOLO MC, MERRETT MN, CROTTY B, JEWELL DP. 5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon. Gut 1996; 38: 115-119.
42. SUENAERT P, BULTEEL V, LEMMENS L, NOMAN M, GEYPENS B, VAN ASSCHE G, GEBOES K, CEUPPENS JL, RUTGEERTS P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002; 97: 2000-2004.
43. ROSENFELDT V, BENFELDT E, VALERIUS NH, PAERREGAARD A, MICHAELSEN KF. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004; 145: 612-616.
44. PATEL RM, MYERS LS, KURUNDKAR AR, MAHESHWARI A, NUSRAT A, LIN PW. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 2012; 180: 626-635.
45. EUN CS, KIM YS, HAN DS, CHOI JH, LEE AR, PARK YK. Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells. APMIS 2011; 119: 49-56.
46. GARCIA VILELA E, DE LOURDES DE ABREU FERRARI M, OSWALDO DA GAMA TORRES H, GUERRA PINTO A, CAR-OLINA CARNEIRO AGUIRRE A, PAIVA MARTINS F, MARCOS ANDRADE GOULART E, SALES DA CUNHA A. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 2008; 43:842-848.
47. ESTEBAN CARRETERO J, DURBAN REGUERA F, LOPEZ-AR-GUETA ALVAREZ S, LOPEZ MONTES J. A comparative analysis of response to vs. ORS + gelatin tannate pediatric patients with acute diarrhea. Rev Esp Enferm Dig 2009; 101: 41-48.
48. GRUJIC-VASIC J, BOSNIC T, JOVANOVIC M. The examining of isolated tannins and their astringent effect. Planta Med 1986: 548.
49. BHEEMACHARI J AK, JOSHI NH, SURESH DK, GUPTA VRM. Antidiarrheal evaluation of Ficus racemosa Linn. latex. Acta Pharm Sci 2007; 49: 133-138.
50. SOUZA SM, AQUINO LC, MILACH AC, JR., BANDEIRA MA, NOBRE ME, VIANA GS. Antiinflammatory and antiulcer properties of tannins from Myracrodruon urundeuva Allemao (Anacardiaceae) in rodents. Phytother Res 2007; 21: 220-225.
51. WIRTZ S, NEUFERT C, WEIGMANN B, NEURATH MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546.
52. DAI C, ZHENG CQ, MENG FJ, ZHOU Z, SANG LX, JIANG M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-kappaB pathway in rat model of DSS-induced colitis. Mol Cell Biochem 2013; 374: 1-11.
53. LIU WS, CHEN MC, CHIU KH, WEN ZH, LEE CH. Amelioration of dextran sodium sulfate-induced colitis in mice by Rhodobacter sphaeroides extract. Molecules 2012; 17: 13622-13630.
54. WONG CC, ZHANG L, LI ZJ, WU WK, REN SX, CHEN YC, NG TB, CHO CH. Protective effects of cathelicidin-encoding Lactococcus lactis in murine ulcerative colitis. J Gastroenterol Hepatol 2012; 27: 1205-1212.
55. HAKANSSON A, BRANNING C, MOLIN G, ADAWI D, HAGS-LATT ML, JEPPSSON B, NYMAN M, AHRNE S. Blueberry husks and probiotics attenuate colorectal inflammation and oncogenesis, and liver injuries in rats exposed to cycling DSS-treatment. PLoS One 2012; 7: e33510.
56. GARRIDO-MESA N, UTRILLA P, COMALADA M, ZORRILLA P, GARRIDO-MESA J, ZARZUELO A, RODRIGUEZ-CABEZAS ME, GALVEZ J. The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem Pharmacol 2011; 82: 1891-1900.
57. HUANG TY, CHU HC, LIN YL, LIN CK, HSIEH TY, CHANG WK, CHAO YC, LIAO CL. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol Appl Pharmacol 2009; 237: 69-82.
58. SCALDAFERRI F LL, PETITO V, CUFINO V, BILOTTA M, ARE-NA V, STIGLIANO E, MAULUCCI G, PAPI M, CARISTO ME, POSCIA A, FRANCESCHI F, DELOGU G, SANGUINETTI M, DE SPIRITO M, SGAMBATO A, GASBARRINI A. Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? United European Gastroenterol J 2014; 2: 113-122.
59. FRASCA G, CARDILE V, PUGLIA C, BONINA C, BONINA F. Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells. Clin Exp Gastroenterol 2012; 5: 61-67.